Analyst
Piper Sandler
Equibles does not estimate personal net worth.
David Amselen is recorded as Analyst at Piper Sandler. David Amselen has spoken on 2 earnings calls and 2 other investor events across 4 companies, most recently for Biogen Inc. on July 29, 2026. Those appearances were for Biogen Inc. (BIIB), AbbVie Inc. (ABBV), Collegium Pharmaceutical, Inc (COLL) and Amneal Pharmaceuticals, Inc. (AMRX). The companies whose calls David Amselen spoke on are classified in the Healthcare sector.
“So on MPaveli, I noticed you are initiating a Phase II in FSGS. Wondering broadly how wide of a development net you're going to cast regarding the molecule just given its complement C3 inhibition and how you're thinking about other indications potentially beyond FSGS.”
“And I guess that question applies to both asthma as well as COPD. Just wondering how broadly you're thinking about that as you think about TSLP only versus IL-13 plus TSLP.”
“So I hate to be the one to ask about other potential acquisitions when you literally just announced one, But I can't help but wonder, you know, just broadly how you're thinking about the business and strategy.”
“I wanted to get your thoughts on the generic OmniPack opportunity and what has been built into your 26 expectations regarding that opportunity. talk about barriers to competition, potential approval of additional strengths, and the extent to which you think that's going to be a limited competition product for the…”
Piper Sandler
Analyst
Transcript header (unverified)
BIIB
Drug Manufacturers - General · Healthcare
ABBV
Drug Manufacturers - General · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
